BCA
ARKG icon

Biltmore Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Biltmore Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,498
Closed -$399K – 142
2021
Q1 		$399K Buy
+4,498
New +$446K 0.09% 87

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SDH
Sloy Dahl & Holst Vancouver, Washington $811M AUM 19.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Biltmore Capital Advisors's ARKG Position: Q2 2021 in Review

Biltmore Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2021, closing a stake of 4,498 shares — an estimated $399K sold.

Biltmore Capital Advisors first reported a position in ARKG in Q1 2021 and held it in 1 quarter. The position peaked at $399K in Q1 2021. 514 funds tracked by Wall St. Rank hold ARKG as of Q2 2021.

  • Biltmore Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2021 after selling out during the quarter.
  • Biltmore Capital Advisors sold 4,498 ARK Genomic Revolution ETF shares in Q2 2021, an estimated $399K.
  • Biltmore Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 1 quarter.
  • Biltmore Capital Advisors's ARK Genomic Revolution ETF position peaked at $399K in Q1 2021.
  • 514 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2021.

Based on Biltmore Capital Advisors's 13F filing for Q2 2021, filed 4 Aug 2021.